3. Wu Q, Jiang L, Li SC, et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin. 2021, 42(1): 1-9. doi: 10.1038/s41401-020-0366-x. 4. 中国抗癌协会肿瘤病理专业委员会,中国临床肿瘤...
[2]Zhao D, Long X, Fan H, Wang J. Effects of hepatic or renal impairment on the pharmacokinetics of immune checkpoint inhibitors. Am J Cancer Res. 2022;12(11):4892-4903. [3] Duan,J., et al., Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 ...
[12] Patel SA, Nilsson MB, Le X, et al. Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. Clin Cancer Res. 2023 Jan 4;29(1):30-39. [13] Gou M, Qian N, Zhang Y, et al. ...
参考文献 [1]. FerraraR, Mezquita L, Texier M, et al. Hyperprogressive disease in patients withadvanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or withsingle-agent chemotherapy. JAMA Oncol 2018;4:1543–52 [2]. ChampiatS, Ferrara R, Massard C, et al. Hyperprogressiv...
Yu JH, Xiao BY, Tang JH, Li DD, Wang F, Ding Y, Han K, Kong LH, Ling YH, Mei WJ, Hong ZG, Liao LE, Yang WJ, Pan ZZ, Zhang XS, Jiang W, Ding PR. Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients. Eur J Cancer. 2023 Oct;192:113253...
4.Wu, Q., Jiang, L., Li, Sc. et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin 42, 1–9 (2021). 5.Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, et al. Structure of the complex of human programmed death 1, ...
PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma 1 研究目的 研究旨在探索基线无脑转移的晚期黑色素瘤患者一线使用ICI/抗PD-1治疗后,是否能降低脑转移的发生风险。 2 研究方法 这项双中心回顾性研究纳入了2014年5月至2017年10月接受治疗的转移性黑色素瘤患者。
Gong Jun, Chehrazi-Raffle Alexander, Reddi Srikanth et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.[J] .J Immunother Cancer, 2018, 6: 8.Alsaab Hashem O, Sau Samaresh, Alzhrani Rami ...
7、Rathi N Pillai, Madhusmita Behera, Taofeek K Owonikoko, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature[J]. Cancer. 2018 Jan 15;124(2):271-277. ...
have good therapeutic effect for patients with MSI-H solid tumors. It is estimated that there are more than 300,000 new MSI-H tumor patients in China every year[4], and some of them have no access to effective ...